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Abstract
Background: Adult-onset Still’s disease is a systemic inflammatory disease which presents with uveitis and scleritis
in the eye. Intravitreal dexamethasone implants are used for the treatment of refractory uveitis.
Case presentation: A 19-year-old woman diagnosed to have adult-onset Still’s disease for fevers, joint pain, and a
salmon-colored bumpy rash presented with scleritis and uveitis in the left eye. Topical and systemic steroids with
oral methotrexate failed to control the inflammation. We performed intravitreal injections of dexamethasone
implants for side effects of steroid and refractory ocular inflammation. The therapy resulted in improvements in the
patient’s uveitis with reductions in scleral vessel engorgement and redness. There was no recurrence of uveitis or
scleritis during 4 months following treatment.
Conclusions: Intravitreal injections of dexamethasone implants may result in clinical improvements of refractory
scleritis combined with uveitis.
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Background
Scleritis is an uncommon but severe, painful, and poten-
tially blinding ocular disease characterized by chronic
inflammation of the sclera that is occasionally accom-
panied by uveitis [1]. Although topical or systemic
corticosteroids are typically used for treatment, some-
times combined with systemic immunosuppressive
agents or biologics, some cases have chronic (persistent)
or recurrent inflammation [2–4], which requires other
therapeutic modalities.
Dexamethasone implants (Ozurdex®, Allergan, USA)
are intravitreal, sustained release corticosteroid implants.
Such implants are approved for the treatment of macular
edema secondary to diabetic retinopathy [5] or retinal
vein occlusion [6] and non-infectious posterior uveitis
[7]. The implant slowly releases dexamethasone for up
to 6 months, which makes it effective for the treatment
of frequently recurring diseases such as macular edema
and uveitis, as it may reduce the number of intravitreal
injections required.
In this report, we describe a case of adult-onset Still’s
disease with refractory scleritis and uveitis that was
successfully treated with intravitreal dexamethasone
implants.
Case presentation
A 19-year old female visited our clinic for uncontrolled
scleritis in the left eye. She denied any previous intraoc-
ular inflammation, ocular injury, or surgery but she had
been diagnosed with adult-onset Still’s disease by a
rheumatologist due to persistent fevers, joint pain, and a
salmon-colored bumpy rash, for which systemic steroid
and immunosuppressive agents had been prescribed.
Before her visit to our clinic, she had suffered from
recurrent episodes of scleritis.
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Her vision was 20/20 OD and 20/30 OS at the first
visit. Slit-lamp examination revealed scleral vessel en-
gorgement and redness in the superonasal sclera of the
left eye, which was compatible with sectoral scleritis.
The eye also showed inflammation in the anterior cham-
ber and vitreous, to the degree of grade 2+ according to
the Standardization of Uveitis Nomenclature (SUN)
Working Group [8]. Other than posterior synechia, there
were no other abnormal findings in the anterior segment.
Fundus examination of both eyes revealed a normal pos-
terior pole and retinal periphery. She received subtenon
triamcinolone injections, topical 1 % prednisolone acetate
four times a day, oral prednisolone 30 mg / day (0.5 mg /
kg), and methotrexate 15 mg per week to control the in-
traocular and scleral inflammation. After 12 weeks, des-
pite the systemic therapy, slit-lamp examination revealed
persistent scleritis (Fig. 1a) and vitritis in the left eye
(Fig. 2a). She complained of weight gain and moon face.
However, as articular and other systemic symptoms had
been well controlled by the medication, local therapy
with dexamethasone implant was considered before
the systemic use of biologic agents such as TNF-alpha
antagonists.
Accordingly, we performed intravitreal injection of a
dexamethasone 0.7-mg implant (Ozurdex; Allergan,
Irvine, CA) into the vitreous of the left eye to treat the
patient’s uveitis refractory to topical and systemic treat-
ment. Two weeks later, she informed us that her vision
and redness in the left eye were improved, and her
scleral vessel engorgement and redness were almost re-
solved. One month following the injection, the intraocu-
lar inflammation was improved from cell 2+ to cell trace
in the anterior chamber and from cell 2+ to none in the
vitreous and the scleritis was almost completely resolved
(Figs. 1b and 2b). At the last visit, 4 months after the
dexamethasone implant injection, there had been no re-
currence of scleritis or uveitis although systemic cortico-
steroids had been tapered and discontinued. There were
no drug-related side effects such as increased intraocular
pressure or cataract progression during the follow-up
period. At the final visit, the patient’s vision was 20/22
OD and 20/30 OS.
Conclusions
Adult-onset Still’s disease is a rare systemic inflamma-
tory disease of unknown etiology characterized by the
classic triad of persistent high spiking fevers, joint pain,
and a distinctive salmon-colored bumpy rash [9, 10]. Al-
though prognosis is usually favorable, complications af-
fecting the lungs, heart, or kidney can be life-threatening
[11]. Scleritis and uveitis are severe intraocular compli-
cations occurring in patients with Still’s disease [12]. In
this report, we successfully treated scleritis and uveitis in
a patient with adult-onset Still’s disease that was resist-
ant to remission and characterized by frequent recur-
rence with conventional systemic corticosteroids and
immunosuppressants via intravitreal dexamethasone
implants.
Intravitreal dexamethasone implants are a widely used
and safe treatment for uveitis [13]. In particular, such
treatment can minimize systemic drug-related complica-
tions caused by systemic steroids, immunosuppressive
drugs, or biologicals, as it is delivered locally into the
eye. Considering the young age of the patient, systemic
adverse effects of long-term systemic corticosteroid use,
and frequent recurrence of uveitis, intravitreal injections
Fig. 1 Anterior segment photograph of sectoral scleritis before a and after b intravitreal dexamethasone implant injection. a Despite the long-term
use of topical and systemic steroids, anterior segment photographs reveal scleral vessel engorgement and redness in the superonasal sclera of the left
eye. b At 1 month after intravitreal dexamethasone implant injection, the redness and engorgement of the scleral vessels improved. Combined uveitis
was resolved following the injection
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of dexamethasone implants were used rather than dose
escalation of systemic steroids or immunosuppressants,
as the patient’s main manifestation of disease was ocular
inflammation. Unexpectedly, the patient’s refractory
scleritis also resolved following intravitreal dexametha-
sone implant injection, suggesting the therapeutic effect-
iveness of the therapy for scleritis.
In terms of safety, local therapy with dexamethasone
implants may be a good treatment option for scleritis,
with reduced risk of systemic adverse effects. A previous
report showed that subconjunctival dexamethasone im-
plants may be effective and safe as a local therapy for
non-necrotizing scleritis [14]. However, subconjunctival
administration of depot corticosteroids is considered un-
safe owing to the risk of scleral thinning and perforation
[15, 16]. Although cataract progression, increased in-
traocular pressure, and complications associated with
intravitreal injections should be considered carefully,
intravitreal dexamethasone implants may be an attractive
choice for the treatment of scleritis, particularly if uveitis
is coexistent.
In summary, we report a case of adult-onset Still’s dis-
ease with combined scleritis and uveitis refractory to
conventional topical/systemic steroids and immunosup-
pressants, which resolved after intravitreal dexametha-
sone implant injections. To our best knowledge, this is
the first report describing the therapeutic effect of intra-
vitreal dexamethasone implants for scleritis. Future stud-
ies with larger samples to validate the safety and efficacy
of the therapy for cases with scleritis with or without
uveitis are warranted.
Abbreviation
SUN: Standardization of Uveitis Nomenclature
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